We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
- Authors
Ahlgren, Sara; Wållberg, Helena; Tran, Thuy A; Widström, Charles; Hjertman, Magnus; Abrahmsén, Lars; Berndorff, Dietmar; Dinkelborg, Ludger M; Cyr, John E; Feldwisch, Joachim; Orlova, Anna; Tolmachev, Vladimir
- Abstract
The detection of human epidermal growth factor receptor type 2 (HER2) expression in malignant tumors provides important information influencing patient management. Radionuclide in vivo imaging of HER2 may permit the detection of HER2 in both primary tumors and metastases by a single noninvasive procedure. Small (7 kDa) high-affinity anti-HER2 Affibody molecules may be suitable tracers for SPECT visualization of HER2-expressing tumors. The use of generator-produced (99m)Tc as a label would facilitate the prompt translation of anti-HER2 Affibody molecules into use in clinics.
- Publication
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2009, Vol 50, Issue 5, p781
- ISSN
0161-5505
- Publication type
Journal Article
- DOI
10.2967/jnumed.108.056929